arrow
L

Laura J. Esserman

University of California System
H指数:89
被引数:3.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer

患者来源类器官中的生物标志物指导反应可预测乳腺癌的有效疗法

2026-08-060
OAAI
WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design

WISDOM随机试验比较基于风险与年度乳腺癌筛查:研究队列特征与设计

2026-05-240
OAAI
Biological subphenotypes in severe acute hypoxaemic respiratory failure and acute respiratory distress syndrome using rapid prospective classification (SPARC) in the USA: a multicentre, observational, study

在美国使用快速前瞻性分类(SPARC)识别严重急性低氧性呼吸衰竭和急性呼吸窘迫综合征中的生物亚表型:一项多中心、观察性研究

2026-05-150
PRE
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer

外周血转录组分析预测人乳腺癌的肿瘤亚型及新辅助化免治疗效果

2026-04-220
PRE
Author Correction: Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial

作者更正:系统化数据采集减少了对源数据核查的需求:一项来自第2阶段多中心随机对照平台试验的探索性分析

2026-03-240
OAAI
Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors

循环肿瘤DNA细化新辅助治疗耐药乳腺肿瘤的危险分层

2025-12-090
OAAI
Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial

系统化数据捕获减少了源数据验证的需求:一项来自一项多中心随机对照平台试验的探索性分析

2025-10-290
OAAI
CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial

CHFR 表达以及乳腺癌细胞在体外和I-SPY试验中对抗有丝分裂剂敏感性

2025-10-240
OA
The Effects of Cyproheptadine on Severe COVID-19 From the I-SPY COVID Adaptive Platform Trial

Cyproheptadine对重症COVID-19的影响:来自I-SPY COVID适应性平台试验

2025-10-010
OAAI
Progesterone receptor (PR) intra-tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial

孕酮受体(PR)在绝经前乳腺癌中的肿瘤内异质性:一项随机试验的二次分析

2025-10-010
OAAI
Integrating breast cancer polygenic risk scores at scale in the WISDOM Study: a national randomized personalized screening trial

在WISDOM研究中大规模整合乳腺癌多基因风险评分:一项全国性随机个性化筛查试验

2025-08-300
OAAI
ASO Visual Abstract: Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial

ASO视觉摘要:新辅助化疗后至手术时间对乳腺癌结局的影响:一项基于I-SPY 2临床试验入组患者的研究

2025-08-290
PRE
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial

新辅助化疗后手术时间对乳腺癌结局的影响:一项基于I-SPY 2临床试验入组患者的研究

2025-08-230
PRE
ASO Visual Abstract: Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial

ASO视觉摘要:新辅助化疗对浸润性小叶乳腺癌手术结果及淋巴结阴性转化率的影响:根据I-SPY2临床试验中分子高风险肿瘤的组织学亚型进行分析

2025-08-230
PRE
ASO Visual Abstract: Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial

ASO视觉摘要:多中心新辅助I-SPY2试验中,根据自报种族对腋窝手术管理的差异

2025-08-210
PRE
Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial

新辅助化疗对浸润性小叶乳腺癌手术结果及淋巴结阴性转化影响的评估:基于I-SPY2临床试验中按组织学亚型分析分子高风险肿瘤

2025-07-240
OA
Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial

在多中心新辅助I-SPY2试验中,基于自我识别种族的腋窝手术管理差异

2025-07-230
OA